|
1
|
Goodwin GH, Sanders C and Johns EW: A new
group of chromatin-associated proteins with a high content of
acidic and basic amino acids. Eur J Biochem. 38:14–19. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bustin M, Lehn D and Landsman D:
Structural features of the HMG chromosomal proteins and their
genes. Biochim Biophys Acta. 1049:231–243. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonaldi T, Längst G, Strohner R, Becker PB
and Bianchi ME: The DNA chaperone HMGB1 facilitates
ACF/CHRAC-dependent nucleosome sliding. EMBO J. 21:6865–6873. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travers AA: Priming the nucleosome: a role
for HMGB proteins? EMBO Rep. 4:131–136. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hock R, Furusawa T, Ueda T and Bustin M:
HMG chromosomal proteins in development and disease. Trends Cell
Biol. 17:72–79. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrari S, Finelli P, Rocchi M and Bianchi
M: The active gene that encodes human high mobility group 1 protein
(HMG1) contains introns and maps to chromosome 13. Genomics.
35:367–371. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kornblit B, Munthe-Fog L, Petersen S,
Madsen H, Vindeløv L and Garred P: The genetic variation of the
human HMGB1 gene. Tissue Antigens. 70:151–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Landsman D and Bustin M: A signature for
the HMG-1 box DNA-binding proteins. Bioessays. 15:539–546. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han J, Zhong J, Wei W, et al:
Extracellular high-mobility group box 1 acts as an innate immune
mediator to enhance autoimmune progression and diabetes onset in
NOD mice. Diabetes. 57:2118–2127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dintilhac A and Bernués J: HMGB1 interacts
with many apparently unrelated proteins by recognizing short amino
acid sequences. J Biol Chem. 277:7021–7028. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weir H, Kraulis P, Hill C, Raine A, Laue E
and Thomas J: Structure of the HMG box motif in the B-domain of
HMG1. EMBO J. 12:1311–1319. 1993.PubMed/NCBI
|
|
12
|
Messmer D, Yang H, Telusma G, et al: High
mobility group box protein 1: an endogenous signal for dendritic
cell maturation and Th1 polarization. J Immunol. 173:307–313. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang H, Ochani M, Li J, et al: Reversing
established sepsis with antagonists of endogenous high-mobility
group box 1. Proc Natl Acad Sci USA. 101:296–301. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calogero S, Grassi F, Aguzzi A, et al: The
lack of chromosomal protein Hmg1 does not disrupt cell growth but
causes lethal hypoglycaemia in newborn mice. Nat Genet. 22:276–280.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Müller S, Scaffidi P, Degryse B, et al:
New EMBO member’s review: the double life of HMGB1 chromatin
protein: architectural factor and extracellular signal. EMBO J.
20:4337–4340. 2001.
|
|
16
|
Ulloa L, Batliwalla FM, Andersson U,
Gregersen PK and Tracey KJ: High mobility group box chromosomal
protein 1 as a nuclear protein, cytokine, and potential therapeutic
target in arthritis. Arthritis Rheum. 48:876–881. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brickman JM, Adam M and Ptashne M:
Interactions between an HMG-1 protein and members of the Rel
family. Proc Natl Acad Sci USA. 96:10679–10683. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Bloom O, Zhang M, et al: HMG-1 as
a late mediator of endotoxin lethality in mice. Science.
285:248–251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bianchi ME and Manfredi AA: High-mobility
group box 1 (HMGB1) protein at the crossroads between innate and
adaptive immunity. Immunol Rev. 220:35–46. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lamkanfi M, Sarkar A, Vande Walle L, et
al: Inflammasome-dependent release of the alarmin HMGB1 in
endotoxemia. J Immunol. 185:4385–4392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park JS, Svetkauskaite D, He Q, et al:
Involvement of toll-like receptors 2 and 4 in cellular activation
by high mobility group box 1 protein. J Biol Chem. 279:7370–7377.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kokkola R, Andersson A, Mullins G, et al:
RAGE is the major receptor for the proinflammatory activity of
HMGB1 in rodent macrophages. Scand J Immunol. 61:1–9. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hori O, Brett J, Slattery T, et al: The
receptor for advanced glycation end products (RAGE) is a cellular
binding site for amphoterin. J Biol Chem. 270:25752–25761. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang H, Wang H, Czura CJ and Tracey KJ:
The cytokine activity of HMGB1. J Leukoc Biol. 78:1–8. 2005.
View Article : Google Scholar
|
|
25
|
Merenmies J, Pihlaskari R, Laitinen J,
Wartiovaara J and Rauvala H: 30-kDa heparin-binding protein of
brain (amphoterin) involved in neurite outgrowth. Amino acid
sequence and localization in the filopodia of the advancing plasma
membrane. J Biol Chem. 266:16722–16729. 1991.
|
|
26
|
Taguchi A, Blood DC, del Toro G, et al:
Blockade of RAGE-amphoterin signalling suppresses tumour growth and
metastases. Nature. 405:354–360. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park JS, Gamboni-Robertson F, He Q, et al:
High mobility group box 1 protein interacts with multiple Toll-like
receptors. Am J Physiol Cell Physiol. 290:C917–C924. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park JS, Arcaroli J, Yum HK, et al:
Activation of gene expression in human neutrophils by high mobility
group box 1 protein. Am J Physiol Cell Physiol. 284:C870–C879.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu M, Wang H, Ding A, et al: HMGB1 signals
through toll-like receptor (TLR) 4 and TLR2. Shock. 26:174–179.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ivanov S, Dragoi AM, Wang X, et al: A
novel role for HMGB1 in TLR9-mediated inflammatory responses to
CpG-DNA. Blood. 110:1970–1981. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tian J, Avalos AM, Mao SY, et al:
Toll-like receptor 9-dependent activation by DNA-containing immune
complexes is mediated by HMGB1 and RAGE. Nat Immunol. 8:487–496.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oyama Y, Hashiguchi T, Taniguchi N, et al:
High-mobility group box-1 protein promotes granulomatous nephritis
in adenine-induced nephropathy. Lab Invest. 90:853–866. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iwata Y, Furuichi K, Sakai N, et al:
Dendritic cells contribute to autoimmune kidney injury in
MRL-Faslpr mice. J Rheumatol. 36:306–314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou JG, Dong JY, Zhang LH and Wang J:
Expression of high mobility group box chromosomal protein 1 in mice
with lupus nephritis. Zhejiang Da Xue Xue Bao Yi Xue Ban.
40:200–206. 2011.(In Chinese).
|
|
35
|
Pisetsky DS: HMGB1: a smoking gun in lupus
nephritis? Arthritis Res Ther. 14:1122012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feng X, Hao J, Liu Q, et al: HMGB1
mediates IFN-γ-induced cell proliferation in MMC cells through
regulation of cyclin D1/CDK4/p16 pathway. J Cell Biochem.
113:2009–2019. 2012.
|
|
37
|
Zickert A, Palmblad K, Sundelin B, et al:
Renal expression and serum levels of high mobility group box 1
protein in lupus nephritis. Arthritis Res Ther. 14:R362012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bruchfeld A, Wendt M, Bratt J, et al:
High-mobility group box-1 protein (HMGB1) is increased in
antineutrophilic cytoplasmatic antibody (ANCA)-associated
vasculitis with renal manifestations. Mol Med. 17:29–35. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim J, Sohn E, Kim CS, Jo K and Kim JS:
The role of high-mobility group box-1 protein in the development of
diabetic nephropathy. Am J Nephrol. 33:524–529. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin M, Yiu WH, Wu HJ, et al: Toll-like
receptor 4 promotes tubular inflammation in diabetic nephropathy. J
Am Soc Nephrol. 23:86–102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Penfold SA, Coughlan MT, Patel SK, et al:
Circulating high-molecular-weight RAGE ligands activate pathways
implicated in the development of diabetic nephropathy. Kidney Int.
78:287–295. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Torres VE, Harris PC and Pirson Y:
Autosomal dominant polycystic kidney disease. Lancet.
369:1287–1301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nakamura T, Kawagoe Y, Ueda Y, Yamada S
and Koide H: Hemoperfusion treatment in a septic shock patient with
autosomal dominant polycystic kidney disease and increased HMGB1
protein levels. Blood Purif. 32:139–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nakamura T, Sato E, Fujiwara N, et al:
Changes in urinary albumin excretion, inflammatory and oxidative
stress markers in ADPKD patients with hypertension. Am J Med Sci.
343:46–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hu YM, Pai MH, Yeh CL, Hou YC and Yeh SL:
Glutamine administration ameliorates sepsis-induced kidney injury
by downregulating the high-mobility group box protein-1-mediated
pathway in mice. Am J Physiol Renal Physiol. 302:F150–F158. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang Q, Yao YM, Wang YB, et al: Effect of
ethyl pyruvate on renal high mobility group box-1 protein
expression and acute kidney injury in rats with delayed
resuscitation after thermal injury. Zhonghua Wai Ke Za Zhi.
45:1210–1213. 2007.(In Chinese).
|
|
47
|
Chen J, Hartono JR, John R, et al: Early
interleukin 6 production by leukocytes during ischemic acute kidney
injury is regulated by TLR4. Kidney Int. 80:504–515. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chung KY, Park JJ and Kim YS: The role of
high-mobility group box-1 in renal ischemia and reperfusion injury
and the effect of ethyl pyruvate. Transplant Proc. 40:2136–2138.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu H, Ma J, Wang P, et al: HMGB1
contributes to kidney ischemia reperfusion injury. J Am Soc
Nephrol. 21:1878–1890. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li J, Gong Q, Zhong S, et al:
Neutralization of the extracellular HMGB1 released by ischaemic
damaged renal cells protects against renal ischaemia-reperfusion
injury. Nephrol Dial Transplant. 26:469–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bao YS, Na SP, Zhang P, et al:
Characterization of interleukin-33 and soluble ST2 in serum and
their association with disease severity in patients with chronic
kidney disease. J Clin Immunol. 32:587–594. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bruchfeld A, Qureshi AR, Lindholm B, et
al: High mobility group box protein-1 correlates with renal
function in chronic kidney disease (CKD). Mol Med. 14:109–115.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sato F, Maruyama S, Hayashi H, et al: High
mobility group box chromosomal protein 1 in patients with renal
diseases. Nephron Clin Pract. 108:c194–c201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Leelahavanichkul A, Huang Y, Hu X, et al:
Chronic kidney disease worsens sepsis and sepsis-induced acute
kidney injury by releasing high mobility group box protein-1.
Kidney Int. 80:1198–1211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nakamura T, Sato E, Fujiwara N, et al:
Positive association of serum levels of advanced glycation end
products and high mobility group box-1 with asymmetric
dimethylarginine in nondiabetic chronic kidney disease patients.
Metabolism. 58:1624–1628. 2009. View Article : Google Scholar
|
|
56
|
D’Agati V and Schmidt AM: RAGE and the
pathogenesis of chronic kidney disease. Nat Rev Nephrol. 6:352–360.
2010.
|
|
57
|
Lynch J, Nolan S, Slattery C, Feighery R,
Ryan MP and McMorrow T: High-mobility group box protein 1: a novel
mediator of inflammatory-induced renal epithelial-mesenchymal
transition. Am J Nephrol. 32:590–602. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sandim V, Pereira D, Ornellas A and Alves
G: Renal cell carcinoma and proteomics. Urol Int. 84:373–377. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lin L, Zhong K, Sun Z, Wu G and Ding G:
Receptor for advanced glycation end products (RAGE) partially
mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.
J Cancer Res Clin Oncol. 13:11–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ganji MR and Harririan A: Chronic
allograft dysfunction: major contributing factors. Iran J Kidney
Dis. 6:88–93. 2012.PubMed/NCBI
|
|
61
|
Wang S, Schmaderer C, Kiss E, et al:
Recipient Toll-like receptors contribute to chronic graft
dysfunction by both MyD88- and TRIF-dependent signaling. Dis Model
Mech. 3:92–103. 2010. View Article : Google Scholar : PubMed/NCBI
|
